Apoc II Mimetic Peptides Patent Application

The EPO published patent application EP3571216A1 on March 25, 2026, for Apoc II mimetic peptides with co-applicants the United States Department of Health and Human Services and Novo Nordisk A/S. The application is classified under C07K 14/00, C07K 14/435, and A61K 38/00 and designates all EPC contracting states.

This is a patent publication notice with no immediate compliance obligations for third parties. Pharmaceutical companies developing cardiovascular or metabolic therapies should monitor this application for potential freedom-to-operate implications. The patent, once granted, will provide exclusivity rights in the designated European states.